2026 Meeting Materials, Vaccines and Related Biological Products Advisory Committee
June 18, 2026
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On June 18, 2026, the Committee will meet in open session to discuss and make recommendations on the safety and effectiveness of MFLUSIVA (Influenza Vaccine, mRNA), manufactured by Moderna TX Inc., with a requested indication in Biologics License Application STN 125869/0 for the prevention of influenza disease caused by influenza virus subtypes A and type B represented in the vaccine, in persons 50 years of age and older.
May 28, 2026
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On May 28, 2026, the Committee will meet in open session to discuss and make recommendations on the selection of the 2026-2027 Formula for COVID-19 vaccines for use in the United States.
March 12, 2026
The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
On March 12, 2026, the Committee will meet in open session to discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2026-2027 influenza season.